Trial Profile
Investigator-Sponsored Protocol - Continued Use of Ibalizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2018
Price :
$35
*
At a glance
- Drugs Ibalizumab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 14 Aug 2017 Status changed from active, no longer recruiting to completed.
- 04 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2015 to 1 Nov 2017.
- 04 Jun 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 May 2017.